Low-dose Albumin Solution in SBP: a Randomized Double-blind Pilot Study
Status:
Unknown status
Trial end date:
2011-03-01
Target enrollment:
Participant gender:
Summary
Spontaneous bacterial peritonitis (SBP) is a common and severe complication of cirrhosis. The
most serious complication of SBP is the hepatorenal syndrome (HRS), which occurs in up to 30
percent of patients, with high mortality. Intravenous albumin (1.5 g/kg at diagnosis and 1
g/kg 48 hours later - standard regimen) helps to prevent HRS and improves survival. No
information exists on the efficacy of lower doses of albumin. This study was designed to
allow direct comparison among different doses of intravenous albumin in patients with SBP -
standard (SR) vs dose reduced regimen (DRR) - in order to prevent renal failure and
mortality.